InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Thursday, 08/05/2021 1:02:39 PM

Thursday, August 05, 2021 1:02:39 PM

Post# of 76
The company announced an agreement with MRNA, granting them an exclusive license to develop and commercialise mRNA therapeutics incorporating proprietary binders for up to four IO targets. AUTL would be eligible to receive an upfront payment for each target licensed and development and commercial milestone payments for each product successfully commercialised. In addition, entitled to receive royalties on net sales of all products commercialised under the agreement.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUTL News